Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup
- PMID: 8782129
Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup
Abstract
Objective: To determine the efficacy and safety of vitamin D 50,000 units/week and calcium 1,000 mg/day in the prevention of corticosteroid induced osteoporosis.
Methods: A minimized double blind, placebo controlled trial in corticosteroid treated subjects in a tertiary care university affiliated hospital. The sample was 62 subjects with polymyalgia rheumatica, temporal arteritis, asthma, vasculitis, or systemic lupus erythematosus. The primary outcome measure was the percentage change in bone mineral density (BMD) of the lumbar spine in the 2 treatment groups from baseline to 36 mo followup.
Results: BMD of the lumbar spine in the vitamin D and calcium treated group decreased by a mean (SD) of 2.6% (4.1%) at 12 mo, 3.7% (4.5%) at 24 mo, and 2.2% (5.8%) at 36 mo. In the placebo group there was a decrease of 4.1% (4.1%) at 12 mo, 3.8% (5.6%) at 24 mo, and 1.5% (8.8%) at 36 mo. The observed differences between groups were not statistically significant. The difference at 36 mo was-0.693% (95% CI -5.34, 3.95).
Conclusion: Vitamin D and calcium may help prevent the early loss of bone seen in the lumbar spine as measured by densitometry of the lumbar spine. Longterm vitamin D and calcium in those undergoing extended therapy with corticosteroids does not appear to be beneficial.
Comment in
-
Prevention of corticosteroid induced osteoporosis.J Rheumatol. 1997 Feb;24(2):407. J Rheumatol. 1997. PMID: 9035007 No abstract available.
Similar articles
-
Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss.J Rheumatol. 1994 Oct;21(10):1922-6. J Rheumatol. 1994. PMID: 7837160 Clinical Trial.
-
Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.J Rheumatol. 2009 Aug;36(8):1705-14. doi: 10.3899/jrheum.081207. Epub 2009 Jun 1. J Rheumatol. 2009. PMID: 19487264 Clinical Trial.
-
Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.AIDS. 2007 Nov 30;21(18):2473-82. doi: 10.1097/QAD.0b013e3282ef961d. AIDS. 2007. PMID: 18025884 Clinical Trial.
-
The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach.Arthritis Rheum. 1999 Aug;42(8):1740-51. doi: 10.1002/1529-0131(199908)42:8<1740::AID-ANR25>3.0.CO;2-E. Arthritis Rheum. 1999. PMID: 10446876 Review.
-
[Post-steroidal osteoporosis].Przegl Lek. 1999;56(2):157-60. Przegl Lek. 1999. PMID: 10375951 Review. Polish.
Cited by
-
Corticosteroid-Induced osteoporosis: detection and management.Drug Saf. 2001;24(8):607-24. doi: 10.2165/00002018-200124080-00005. Drug Saf. 2001. PMID: 11480493 Review.
-
The role of vitamin D supplementation in patients with rheumatic diseases.Nat Rev Rheumatol. 2013 Jul;9(7):411-22. doi: 10.1038/nrrheum.2013.71. Epub 2013 May 14. Nat Rev Rheumatol. 2013. PMID: 23670134 Review.
-
Role of teriparatide in treatment of glucocorticoid-induced osteoporosis.Ther Clin Risk Manag. 2010 Oct 21;6:497-503. doi: 10.2147/TCRM.S7776. Ther Clin Risk Manag. 2010. PMID: 21063460 Free PMC article.
-
Medication-induced osteoporosis.Curr Osteoporos Rep. 2007 Dec;5(4):139-45. doi: 10.1007/s11914-007-0008-y. Curr Osteoporos Rep. 2007. PMID: 18430387 Review.
-
Understanding and Managing Corticosteroid-Induced Osteoporosis.Open Access Rheumatol. 2021 Jul 2;13:177-190. doi: 10.2147/OARRR.S282606. eCollection 2021. Open Access Rheumatol. 2021. PMID: 34239333 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical